Abstract
Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Mini-Reviews in Medicinal Chemistry
Title:Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents
Volume: 18 Issue: 4
Author(s): Jinlian Wei, Yingrui Yang, Mengchen Lu, Yonghua Lei, Lili Xu, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Haopeng Sun*Qidong You
Affiliation:
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009,China
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Abstract: Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Export Options
About this article
Cite this article as:
Wei Jinlian, Yang Yingrui, Lu Mengchen, Lei Yonghua, Xu Lili, Jiang Zhengyu, Xu Xiaoli, Guo Xiaoke, Zhang Xiaojin, Sun Haopeng*, You Qidong, Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents, Mini-Reviews in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1389557516666160630124938
DOI https://dx.doi.org/10.2174/1389557516666160630124938 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidants in Asthma and in Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Evaluation of Contrast-enhanced Transcranial Color-coded Duplex Sonography (CE-TCCD) Applied in Stroke Patients with Intracranial Collateral Circulation
Current Medical Imaging Calcium Level Controlling Activities of Novel Derivatives of Amlodipine,Riodipine and Cerebrocrast
Letters in Drug Design & Discovery Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
CNS & Neurological Disorders - Drug Targets The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?
Current Medicinal Chemistry Novel Strategies for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Drug Eluting Stents and Beyond
Current Pharmaceutical Design L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes
Current Medicinal Chemistry Experimental Fracture Protocols in Assessments of Potential Agents for Osteoporotic Fracture Healing Using Rodent Models
Current Drug Targets Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Selected Heterocyclic Compounds as Antioxidants. Synthesis and Biological Evaluation
Current Topics in Medicinal Chemistry The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Advances in Drug Safety
Current Pharmaceutical Design